ScreenerHero

ALMS Alumis Inc.

NAS · US · Healthcare · Biotechnology · alumis.com
6.770USD-2.31%Mkt Cap: 876.28M $P/E: —

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap876.28M USD
Enterprise Value431.12M USD
Revenue (TTM)7.40M USD
Gross Profit7.40M USD
Net Income (TTM)-243.32M USD
Revenue/Share0.06 USD
Last Price6.770 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees237
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.41
PEG—
EV/EBITDA-1.02
EV/Revenue58.28
P/S121.25
P/B1.97
EPS (TTM)-3.86
EPS (Forward)-2.87
52W Range
3.76011% of range30.77
52W High30.77 USD
52W Low3.760 USD
Profitability
Gross Margin100.00%
Oper. Margin-6439.89%
EBITDA Margin0.00%
Profit Margin-1011.75%
ROE-80.76%
ROA-59.07%
Growth
Revenue Growth-37.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-369.52M USD
CapEx (TTM)653.00K USD
FCF Margin-2820.19%
FCF Yield-23.81%
Net Debt-465.87M USD
Net Debt/EBITDA1.11
Balance Sheet
Debt/Equity0.12
Current Ratio6.74
Quick Ratio6.64
Book Value/Sh3.52 USD
Cash/Share3.88 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)32.13 USD
Upside (mean)+374.5%
Target Range15.00 USD – 46.00 USD
15.00+374.5% to mean46.00
# Analysts8
Ownership
Shares Out.129.44M
Float97.18M
Insiders0.53%
Institutions93.61%
Short Interest
Short Ratio1.6d
Short % Float8.11%
Short % Out.4.87%
Shares Short6.30M
Short (prev mo.)5.85M
Technical
SMA 5017.29 (-60.8%)
SMA 20022.11 (-69.4%)
Beta-0.36
S&P 52W Chg16.45%
Avg Vol (30d)3.82M
Avg Vol (10d)2.35M
Technical Indicators
RSI (14)21.2
MACD-2.9600
MACD Signal-3.4982
MACD Hist.+0.5383
BB Upper10.28 USD
BB Middle7.957 USD
BB Lower5.628 USD
BB Width58.52%
ATR (14)0.9013 USD
Vol Ratio (20d)0.70x